Profile of nelarabine: Use in the treatment of T-cell acute lymphoblastic leukemia

OncoTargets and Therapy

Volumn 2, Issue , 2009, Pages 219-228

  Reilly, Kelly M ^a   Kisor, David F ^a  

^a OHIO NORTHERN UNIVERSITY   (United States)

Author keywords

9 beta D arabinofuranosyl guanine; ara G; Nelarabine; T cell acute lymphoblastic leukemia

Indexed keywords

CYTARABINE; FLUDARABINE; GUANINE ARABINOSIDE; IMIPENEM; NELARABINE; PENTOSTATIN; VINCRISTINE;

ACUTE LYMPHOCYTIC LEUKEMIA; AMNESIA; ANOREXIA; AREA UNDER THE CURVE; ATAXIA; B CELL LEUKEMIA; BALANCE DISORDER; BLAST CELL CRISIS; CANCER PATIENT; CANCER REGRESSION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL EFFECTIVENESS; COMA; COMBINATION CHEMOTHERAPY; CONSCIOUSNESS; CREATININE CLEARANCE; CYTOTOXICITY; DIARRHEA; DIZZINESS; DNA SYNTHESIS INHIBITION; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEVER; HEADACHE; HUMAN; HYPESTHESIA; KIDNEY FUNCTION; MALAISE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MONONUCLEAR CELL; MONOTHERAPY; MOTOR DYSFUNCTION; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PARESTHESIA; PERIPHERAL NEUROPATHY; PLASMA HALF LIFE; PROLYMPHOCYTIC LEUKEMIA; REPEATED DRUG DOSE; REVIEW; SEIZURE; SENSORY NEUROPATHY; SIDE EFFECT; SOMNOLENCE; STOMATITIS; T CELL LEUKEMIA; T LYMPHOBLAST; TASTE DISORDER; TENDON REFLEX; THROMBOCYTOPENIA; TREATMENT RESPONSE; TREMOR; VOMITING;

EID: 77953387810     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukemia. Lancet. 2008;371:1030-1043.
2. Esparza S. Topics in pediatric medicine - acute lymphoblastic leukemia. Med Gen Med [PMC1681386]. 2005 Feb [cited 2009 March 10]; 7(1):[about 1p.]. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1681386 (Pubitemid 41349743)
3. Song KW, Barnett MJ, Gascoyne M, et al. Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomes. Ann Oncol. 2007;18:535-540.
4. Getting the Facts: T-cell Lymphomas. Lymphoma Research Foundation; 2008 March:1-4.
5. Gandhi V, Plunkett W, Weller S, et al. Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia Cells. J Clin Oncol. 2001;19:2124-2152. (Pubitemid 32366968)
6. Kurtzberg J. Guanine arabinoside as a bone marrow purging agent. Ann NY Acad Sci. 1993;658:225-236. (Pubitemid 23238494)
7. Gravatt LC, Chaffee S, Hebert ME, et al. Efficacy and toxicity of 9-beta-D-arabinofuranosylguanine (araG) as an agent to purge malignant T-cells from murine bone marrow: Application to an in vivo T-leukemia model. Leukemia. 1993;7:1261-1267. (Pubitemid 23256480)
8. Kisor D, Plunkett W, Kurtzberg J, et al. Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. J Clin Oncol. 2000;18:995-1003. (Pubitemid 30123775)
9. www.pbm.va.gov [homepage on the Internet]. National PBM Monograph: Nelarabine (Arranon®). [updated 2007 Jan; cited 2009 March 10]. http://www.pbm.va.gov/Clinical%20Guidance/Drug%20Monographs/Nelarabine.pdf
10. DeAngelo D. The treatment of adolescents and young adults with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2005:123-130.
11. Rodriquez CO, Mitchell BS, Ayres M, Eriksson S, Ghandi V. Arabinosyl-guanine is phosphorylated by cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. Cancer Res. 2002;62:3000-3005. (Pubitemid 34602401)
12. Rodriguez CO, Ghandi V. Arabinosylguanine-induced apoptosis of T-lymphoblastic cells: incorporation into DNA is a necessary step. Cancer Res. 1999;59:4937-4943.
13. Rodriguez CO, Stellrecht CM, Gandhi V. Mechanism for T-cell selective cytotoxicity of arabinosylguanine. Blood. 2003;102:1842-1848. (Pubitemid 37022581)
14. Ghandi V, Plunkett W, Rodriguez CO, et al. Compound GW506U78 in refractory hematologic malignancies: Relationship between cellular pharmacokinetics and clinical response. J Clin Oncol. 1998;16:3607-3615. (Pubitemid 28506775)
15. DeAngelo DJ, Yu D, Johnson JL, et al. Nelarabine induces complete remission in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood. 2007;109:5136-5142. (Pubitemid 46890527)
16. Rodriguez CO, Legha JK, Estey E, et al. Pharmacological and biochemical strategies to increase the accumulation of arabinofuranosylguanine triphosphate in primary human leukemia cells. Clin Cancer Res. 1997;3:2107-2113. (Pubitemid 27505139)
17. Gandhi V, Tam C, O'Brien, et al. Phase I trial of nelarabine in indolent leukemias. J Clin Oncol. 2008;26:1098-1105.
18. Kurtzberg J, Ernst TJ, Keating MJ, et al. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol. 2005;23:3396-3403. (Pubitemid 46243483)
19. Goy A, Bleyer A, Hagemeister F, et al. Phase II study of compound GW506U78 (araG) for patients with indolent B-cell or peripheral T-cell lymphoma previously treated with chemotherapy. Proceedings of the 45th Annual Meeting American Society of Hematology; 2003; San Diego, U S A. Abstract 2359.
20. Berg SL, Blaney SM, Devidas M, et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: A report from the Children's Oncology Group. J Clin Oncol. 2005;23:3376-3382. (Pubitemid 46243482)
21. www.fda.gov [homepage on the Internet]. Questions for the Oncology Drug Advisory Committee; [2005 Sept 14; cited 2009 March 10]. http://www.fda.gov/ ohrms/dockets/ac/05/questions/2005-4174Q2-02-Arranon.pdf